A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer.

ABSTRACT:

Background

The last decade saw the emergence of several new systemic therapies for metastatic hormone-sensitive prostate cancer (mHSPC). While these treatments demonstrated similar efficacy in indirect comparisons, comparisons of safety outcomes are needed to help guide the selection of treatment regimens and sequences. We conducted network meta-analyses (NMAs) comparing safety of systemic treatments for mHSPC.

Methods

A systematic literature review was performed for randomized controlled trials (RCTs) investigating systemic treatments for mHSPC published before July 2022. Studies were restricted by network connectivity and study population homogeneity. Bayesian NMAs were performed for available data on grade ≥3 adverse events (AEs), serious AEs (SAEs), and any AE.

Result

SUBMITTER: Di Maio M 

PROVIDER: S-EPMC12498157 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature